Clinical Trials Logo

Penile Cancer clinical trials

View clinical trials related to Penile Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06465914 Not yet recruiting - Anal Cancer Clinical Trials

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Start date: July 30, 2024
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Human Papillomavirus (HPV) Recombinant Vaccine (Hansenula Polymorpha) in Chinese male subjects aged 18-45 years. The primary hypothesis in the study is the 9-valent HPV recombinant vaccine reduces the incidence of vaccine HPV types-related genital warts compared with placebo in Chinese men.

NCT ID: NCT06415318 Not yet recruiting - Penile Cancer Clinical Trials

TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

Primary Objective: To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with Toripalimab as a neoadjuvant treatment in locally advanced penile cancer

NCT ID: NCT06353906 Not yet recruiting - Urologic Neoplasms Clinical Trials

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

PRIAM
Start date: June 14, 2024
Phase: Phase 2
Study type: Interventional

This is a single-armed, single-centre, non-blinded phase II trial to assess efficacy of induction chemo-immunotherapy for resectable node-positive squamous cell carcinoma of the penis

NCT ID: NCT05662839 Not yet recruiting - Penile Cancer Clinical Trials

Feasibility of Utilising Brushing Cytology and Dermoscopy for Diagnosing Penile Lesions

BRUCY
Start date: January 2023
Phase: N/A
Study type: Interventional

In an attempt to reduce patient flow into the hospital we are going to assess the use of penile cytological brushings and dermoscopy in diagnosing cancer or non-cancer conditions of the penis.

NCT ID: NCT05639972 Not yet recruiting - Cervical Cancer Clinical Trials

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Start date: June 12, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. The intent of E7 TCR-T cell treatment is to shrink or eliminate tumors and thereby facilitate definitive therapy and increase overall survival. This study seeks to determine 1) if E7 TCR-T cell can be administered without undue delay in definitive treatment, 2) the tumor response rate to E7 TCR-T cell treatment, 3) and the disease-free survival rate at 2 and 5 years. Participants will undergo an apheresis procedure to obtain T cells that will be genetically engineered to generate E7 TCR-T cells. They will receive a conditioning regimen, a single infusion of their own E7 TCR-T cells, and adjuvant aldesleukin. Participants will follow up to assess safety and determine tumor response and will return to their primary oncology team for definitive therapy.